CLINICAL TRIALS PROFILE FOR TALAROZOLE
✉ Email this page to a colleague
Clinical Trials for Talarozole
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00716144 ↗ | Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis | Completed | GlaxoSmithKline | Phase 2 | Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and efficacy of R115866 will be evaluated during the treatment period and the 8-week post treatment follow-up period. |
NCT00716144 ↗ | Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis | Completed | Stiefel, a GSK Company | Phase 2 | Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and efficacy of R115866 will be evaluated during the treatment period and the 8-week post treatment follow-up period. |
NCT00719121 ↗ | Study on Anti-inflammatory Effects of Topical R115866 Gel | Completed | Stiefel, a GSK Company | Phase 1 | The purpose of this exploratory trial is to assess the anti-inflammatory effect(s) of topical R115866 in a model of UVB-induced inflammation and in a model of cutaneous irritation. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Talarozole
Condition Name
Clinical Trial Locations for Talarozole
Clinical Trial Progress for Talarozole
Clinical Trial Phase
Clinical Trial Sponsors for Talarozole
Sponsor Name